| 产品名称 | Peptides EP12631_1 | WT1 126-134 mutant (HLA-A*02:01) 126Y |
|---|---|
| 目录号 | EP12631_1 |
| 别名 | WT1 126-134 mutant (HLA-A*02:01) 126Y |
| 外观 | 见COA |
| 分子量 | N/A |
| CAS | N/A |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
| 目录号 | 规格 | 价格 | 库存状态 | |
| EP12631_1 | 1 mg; 5 mg | 咨询 | 咨询 |
Peptides EP12631_1 | WT1 126-134 mutant (HLA-A*02:01) 126Y
品名：WT1 126-134 mutant (HLA-A*02:01) 126Y
货号：EP12631_1
规格：1 mg; 5 mg
品牌：Peptides.de
产品描述
Wilms tumor protein is a protein that is encoded by the WT1 gene on chromosome 11p in humans. WT1 is a tumour suppressor gene associated with the development of Wilms' Tumour, from which it was named. Mutations in exon 7 and 9 of WT1 have been recurrently identified in acute myeloid leukemia and associated with poorer prognosis and chemotherapy resistance. The WT1 peptide is a transcription factor that contains four zinc finger motifs at the C-terminus and a proline / glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system. WT1 has been ranked by the National Cancer Institute (NCI) as the Number 1 target for cancer immunotherapy. This gene encodes a transcription factor that contains four zinc-finger motifs at the C-terminus and a proline/glutamine-rich DNA-binding domain at the N-terminus. It has an essential role in the normal development of the urogenital system, and it is mutated in a small subset of patients with Wilms tumor. This gene exhibits complex tissue-specific and polymorphic imprinting pattern, with biallelic, and monoallelic expression from the maternal and paternal alleles in different tissues. Multiple transcript variants have been described. YMFPNAPYL is a linear peptidic epitope (epitope ID 158523), tested in MHC ligand assays.
| Protein | Wilms-Tumor-Protein |
| Species | Human |
| Application | T-cell assays, Immune monitoring, Antigen specific T-cell stimulation, T-cell expansion, Cellular immune response |
| Indication | Cancer |
